

October 31, 2011

ORIGIO a/s
A world leader in Assisted Reproductive Technologies (ART)

ORIGIO Initiates Warrant Programme for Executive Management

ORIGIO a/s, a medtech company listed on the Oslo Stock Exchange (OSE: ORO), announced today that the Board of Directors has granted a total of 595,000 warrants to the Executive Management team of ORIGIO a/s under its current mandate.

Each warrant gives the holder the right to subscribe to 1 ordinary share in ORIGIO a/s at a nominal value of DKK 5.00. The exercise price for each warrant equals the official closing price for the ORIGIO share on the Oslo Stock Exchange on October 28, 2011 (NOK 14.00). The warrant programme is constructed so that the warrants will not be exercisable if the compound annual growth rate of the share price of ORIGIO a/s is not a minimum of 6.0% per annum at the time of exercise of the warrant versus the closing price on Oslo Stock Exchange on October 28, 2011.

Under this program the CEO has been granted 175,000 warrants and other members of executive management 70,000 warrants each. The warrants will be earned over a three years period starting November 1, 2011.

For further information, please contact:

Jesper Funding Andersen, CEO: +45 4073 0963 or email, jfandersen@origio.com

Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or email, jbrix@origio.com

About ORIGIO a/s

ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families, MediCult Media, Humagen Pipets and MidAtlantic Devices, that cater for the broadest range of ART requirements. The medtech company ORIGIO, which is headquartered in Måløv, Denmark, and has subsidiaries in 10 countries, is listed on the Oslo Stock Exchange under the symbol, ORO. For further information, please visit www.origio.com.

Forward-Looking Statements

Certain statements in this announcement contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this announcement will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO's anticipated schedule. These factors, and other factors including, but not limited to, those described in ORIGIO's most recent annual report, could cause future results to differ materially from the expectations expressed in this announcement. The forward-looking statements contained in this announcement may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.